Exosomes for Immunotherapy of Cancer
Exosomes are 60 to 90 nm membrane vesicles originating from late endosomes and secreted from most hematopoietic and epithelial cells in vitro. B cell derived-exosome antigenicity was first reported in 1996 in MHC class II restricted CD4+ T lymphocytes. In 1998, we reported that dendritic cell derived-exosomes are immunogenic in mice leading to tumor rejection. These findings have renewed the interest in exosomes. The current challenge consists in understanding the mechanisms and the physiological relevance of exosomes that could contribute to the design of the optimal exosome based-vaccination. Here, we will focus on the biological features pertaining to dendritic cell-and tumor cell derived-exosomes and will discuss their potential clinical implementation.
KeywordsTumor Antigen Late Endosome Tumor Rejection Malignant Effusion Tumor Rejection Antigen
Unable to display preview. Download preview PDF.
- 8.Raposo, G. et al. Accumulation ofmajor histocompatibility complex class II molecules in mast cell secretory granules and their release upon degranulation. Molec. Biol. Cell 1997; 8: 2631–2645.Google Scholar
- 10.Arnold, P.Y. and Mannie, M.D. Vesicles bearing MHC class II molecules mediate transfer of antigen-presenting cells to CD4+ cells. Eur. J. Immunol 1999;29:1363–1373.Google Scholar
- 19.Raposo, G. et al. B lymphocytes secrete antigen-presenting vesicles. J. Exp. Med. 1996;183: 11611172.Google Scholar
- 26.Théry C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nature Review Immunol. 2002; 2: 569–579.Google Scholar
- 27.Théry C, Duban L, Segura E, Véron P, Lantz O, Amigorena S. Exosomes activate naive CD4+ T cells by transfer of MHC/peptide complexes to dendritic cells. Nat. Immunol. In press.Google Scholar
- 29.Escudier B, Dorval T, Angevin E, Boccaccio C, Robert C, Avril MF, Lantz O, Bonnerot C, Tursz T, Dhellin O, Serra V, Valente N, Le-Pecq JB, Zitvogel L. Novel approach to immunotherapy of cancer: Phase I trial of dexosome vaccine for patients with advanced melanoma. Proc. Am. Soc. Clin. Oncol. 2002; A1857.Google Scholar